Struggling Generic Drugmakers Face M&A Dilemma: Expand and Complicate or Stand Pat and Risk It All

Struggling Generic Drugmakers Face M&A Dilemma: Expand and Complicate or Stand Pat and Risk It All


In November the pharma world was buzzing over news reports that Novartis was seeking to acquire generics maker Amneal Pharmaceuticals LLC, in a deal that could fetch around $8 billion. Acquiring Bridgewater, N.J.-based Amenal would help Novartis's generics unit, Sandoz International GmbH, maintain its spot as the third-largest U.S. generics maker as other generics leaders have been buying up smaller rivals.



from Biotech News